Shares of Zoetis Inc (NYSE:ZTS) have earned an average recommendation of “Buy” from the twenty brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and fourteen have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $79.83.
ZTS has been the subject of a number of analyst reports. Zacks Investment Research downgraded Zoetis from a “hold” rating to a “sell” rating and set a $83.00 price objective for the company. in a research report on Saturday, January 13th. Morgan Stanley raised Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price objective for the company in a research report on Wednesday, November 29th. Jefferies Group reissued a “buy” rating on shares of Zoetis in a research report on Friday, November 10th. Craig Hallum reissued a “buy” rating and set a $85.00 price objective (up from $77.00) on shares of Zoetis in a research report on Tuesday, January 2nd. Finally, BidaskClub raised Zoetis from a “hold” rating to a “buy” rating in a research report on Tuesday, November 7th.
A number of hedge funds have recently bought and sold shares of the stock. We Are One Seven LLC purchased a new stake in Zoetis during the fourth quarter worth approximately $120,000. OLD Mutual Customised Solutions Proprietary Ltd. lifted its stake in Zoetis by 62.8% in the fourth quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 23,585 shares of the company’s stock valued at $1,699,000 after buying an additional 9,100 shares during the last quarter. Altman Advisors Inc. purchased a new stake in Zoetis in the fourth quarter valued at approximately $1,953,000. MetLife Investment Advisors LLC purchased a new stake in Zoetis in the fourth quarter valued at approximately $10,862,000. Finally, Gotham Asset Management LLC lifted its stake in Zoetis by 40.7% in the fourth quarter. Gotham Asset Management LLC now owns 5,612 shares of the company’s stock valued at $404,000 after buying an additional 1,624 shares during the last quarter. Hedge funds and other institutional investors own 94.18% of the company’s stock.
Shares of Zoetis (NYSE ZTS) traded up $1.23 during trading on Wednesday, hitting $79.73. The stock had a trading volume of 3,958,800 shares, compared to its average volume of 3,085,336. Zoetis has a 1-year low of $52.25 and a 1-year high of $81.40. The firm has a market capitalization of $38,689.28, a P/E ratio of 45.56, a PEG ratio of 1.80 and a beta of 1.06. The company has a debt-to-equity ratio of 2.77, a quick ratio of 2.55 and a current ratio of 3.85.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 15th. The company reported $0.69 EPS for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.03. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.40 billion. During the same period in the previous year, the company posted $0.47 earnings per share. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. analysts forecast that Zoetis will post 3.02 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, April 20th will be paid a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a yield of 0.63%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s payout ratio is 28.57%.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://ledgergazette.com/2018/03/14/zoetis-inc-zts-receives-consensus-rating-of-buy-from-analysts.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.